NCT05092412 is a Phase 2 clinical trial of Low-dose radiotherapy in Lung Cancer, sponsored by You Lu.

Who is sponsoring NCT05092412?

NCT05092412 is sponsored by You Lu.

What drugs are being tested in NCT05092412?

Interventions in NCT05092412: Low-dose radiotherapy, Durvalumab, Etoposide, and cisplatin/carboplatin.

What condition does NCT05092412 study?

NCT05092412 studies Lung Cancer, Extensive-stage Small-cell Lung Cancer, Durvalumab.

Is NCT05092412 still recruiting?

NCT05092412 is currently status unknown. Last updated 12 January 2024.

Last reviewed 2024-01-12 · How we verify

NCT05092412

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

Status unknown Phase 2 Last updated 12 January 2024

What this trial tests

Phase 2 trial testing Low-dose radiotherapy in Lung Cancer in 30 participants. Status unknown.

Timeline

2 March 2022

Primary endpoint
6 February 2023

30 June 2025

Quick facts

Lead sponsor	You Lu
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	2 March 2022
Primary completion	6 February 2023
Estimated completion	30 June 2025
Sites	3 locations across China

Drugs / interventions tested

Low-dose radiotherapy
Durvalumab — full drug profile →
Etoposide, and cisplatin/carboplatin — full drug profile →

Conditions studied

Lung Cancer — all drugs for Lung Cancer →
Extensive-stage Small-cell Lung Cancer — all drugs for Extensive-stage Small-cell Lung Cancer →
Durvalumab — all drugs for Durvalumab →

Sponsor

You Lu — full company profile →

Who can join

18 and older, any sex, with Lung Cancer or Extensive-stage Small-cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study was to evaluate the efficacy of low-dose radiotherapy (LDRT) combined with durvalumab, etoposide, and cisplatin/carboplatin in the first-line treatment of extensive-stage small cell lung cancer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives.
Zhang S, Cheng Y. · · 2023 · cited 26× · PMID 37188176 · DOI 10.3389/fonc.2023.1142081
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities.
Zhang J, Zeng X, Guo Q, Sheng Z, et al · · 2024 · cited 8× · PMID 39103941 · DOI 10.1186/s40164-024-00548-w
Low-dose radiotherapy remodels the tumor immune microenvironment via the cGAS-STING pathway: mechanisms, challenges, and combination therapy strategies.
He Y, Zeng X, Liu Q, Zhou L, et al · · 2026 · PMID 41803899 · DOI 10.1186/s12943-026-02634-5

Verify or expand the search:

Other trials of Low-dose radiotherapy

Trials testing the same drug.

NCT07448142 — Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer · Phase 2 · recruiting
NCT07371234 — Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck · Phase 2 · recruiting
NCT06732258 — Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC · Phase 1 · not yet recruiting
NCT06791148 — Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Canc · Phase 2 · recruiting
NCT06494995 — AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy · Phase 2 · recruiting

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05092412 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by You Lu
Last refreshed: 12 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05092412.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing